From: Assessment of COVID-19 progression on day 5 from symptoms onset
TOT (n = 235) | Disease progressiona | Univariate | |||
---|---|---|---|---|---|
No (n = 147) | Yes (n = 88) | OR (95% CI) | p-value | ||
Age (years) > 65 | 157 (67%) | 90 (61%) | 67 (76%) | 2.02 (1.12 to 3.65) | 0.020 |
Gender (female) | 87 (37%) | 58 (40%) | 29 (33%) | 0.75 (0.43 to 1.31) | 0.318 |
Comorbidities (any) | 190 (81%) | 119 (81%) | 71 (81%) | 0.98 (0.50 to 1.92) | 0.959 |
Diabetes | 40/190 (21%) | 27/119 (23%) | 13/71 (18%) | 0.76 (0.37 to 1.59) | 0.475 |
Cancer | 33/190 (17%) | 22/119 (19%) | 11/71 (16%) | 0.81 (0.37 to 1.79) | 0.599 |
Cardiovascular diseases | 90/190 (47%) | 45/119 (38%) | 45/71 (63%) | 2.85 (1.55 to 5.23) | 0.001 |
Renal diseases | 39/190 (21%) | 20/119 (17%) | 19/71 (27%) | 0.81 (0.89 to 3.69) | 0.103 |
Respiratory diseases | 34/190 (18%) | 21/119 (18%) | 13/71 (18%) | 1.05 (0.49 to 2.25) | 0.908 |
Liver diseases | 6/190 (3%) | 4/119 (3%) | 2/71 (3%) | 0.83 (0.15 to 4.67) | 0.836 |
BMI > 30 | 16/190 (8%) | 12/119 (10%) | 4/71 (6%) | 0.53 (0.17 to 1.72) | 0.292 |
Neurologic/Psychiatric diseases | 66/190 (35%) | 38/119 (32%) | 28/71 (39%) | 1.39 (0.75 to 2.56) | 0.294 |
Symptoms | |||||
Fever | 193 (82%) | 120 (82%) | 73 (83%) | 1.09 (0.55 to 2.19) | 0.798 |
Cough | 106 (45%) | 68 (46%) | 38 (43%) | 0.88 (0.52 to 1.50) | 0.646 |
Dyspnoea | 87 (37%) | 41 (28%) | 46 (52%) | 2.83 (1.63 to 4.92) | 0.000 |
Treatment | |||||
Steroids (at least 5 days) | 38/183 (21%) | 26/124 (21%) | 12/59 (20%) | 0.96 (0.45 to 2.07) | 0.922 |
Non-invasive ventilation | 26 (11%) | 17 (12%) | 9 (10%) | 0.87 (0.37 to 2.05) | 0.752 |
Invasive mechanical ventilation | 30 (13%) | 2 (1%) | 28 (32%) | 33.83 (7.81 to 156.53) | 0.000 |
Outcomes (days), mean (SD) | |||||
Time from symptoms onset to admission | 3.6 (3.2) | 3.2 (2.4) | 4.0 (3.9) | 0.78 (− 0.08 to 1.63) | 0.076 |
Length hospital stay | 13.2 (11.5) | 12.4 (11.2) | 14.3 (12) | 1.82 (− 1.24 to 4.87) | 0.243 |